Articles By Janet Pope, MD, MPH, FRCPC
Does RA kill you? Let me count the ways….and what you can do about it
There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.
Read ArticleThe Gender Gap in Rheumatology Leaders
Leadership positions in medicine are disproportionately filled by men. Although the enrollment of medical schools are equal male: female or even some have more women, 40% of American medical institutions lack programs for recruiting women, or for retention and promotion of female faculty.This may also be true in rheumatology, which is now attracting more women than men as trainees. I recently wrote an article in the Lancet about mentoring women in medicine and suggested ideas for improving the gender gap in leadership.
Read ArticleHighlights from EULAR 2017 - From RheumReports.com
Dr. Janet Pope reviews her favorite and least favorite presentations and abstracts from EULAR 2017.
Read ArticleWhy Not Just Kick the TNFi Habit?
Why do we use TNF inhibitors as our first biologic choice? Is it the evidence of efficacy, access, safety, and drug retention, or is it a prescriber habit that merits critique?
Read ArticleSmoking and Rheumatoid Arthritis
Why don't rheumatologists send their smoker patients to smoking cessation programs or use aids for cessation? Do we think it is not our problem?
Read ArticleRA Guidelines Shouldn't Ignore the Power of Methotrexate Combo Therapy
The introduction of the 2015 rheumatoid arthritis treatment guidelines has prompted discussion and critique from many. Here's my perspective on where monotherapy and methotrexate combination therapy fits in our armamentarium.
Read ArticleHow Do I Treat Symptomatic Interstitial Lung Disease in Scleroderma?
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
Read ArticleLupus Management After Failure of First-Line Treatment
There are no detailed recommendations agreed upon by SLE experts on what treatment to use after first and second (and often third) line treatment has failed.
Read Article